We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
GenSight Biologics has reported new data from its phase 3 program for GS010, its gene therapy for an ultrarare eye disease, sparking another uptick in its share price....